| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Interleukin-1 receptor-associated kinase 4 |
|---|
| Ligand | BDBM50095475 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1504266 (CHEMBL3592269) |
|---|
| IC50 | 0.200000±n/a nM |
|---|
| Citation |  Lim, J; Altman, MD; Baker, J; Brubaker, JD; Chen, H; Chen, Y; Fischmann, T; Gibeau, C; Kleinschek, MA; Leccese, E; Lesburg, C; Maclean, JK; Moy, LY; Mulrooney, EF; Presland, J; Rakhilina, L; Smith, GF; Steinhuebel, D; Yang, R Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4. ACS Med Chem Lett6:683-8 (2015) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Interleukin-1 receptor-associated kinase 4 |
|---|
| Name: | Interleukin-1 receptor-associated kinase 4 |
|---|
| Synonyms: | IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64 |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 51519.08 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q9NWZ3 |
|---|
| Residue: | 460 |
|---|
| Sequence: | MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALL
QTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITV
QQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNF
DERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKC
QHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGIN
FLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEAL
RGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMND
ADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
|
|
|
|---|
| BDBM50095475 |
|---|
| n/a |
|---|
| Name | BDBM50095475 |
|---|
| Synonyms: | CHEMBL3590479 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C18H22F2N8O |
|---|
| Mol. Mass. | 404.4171 |
|---|
| SMILES | Cn1cc(NC(=O)c2cnn3ccc(N[C@@H]4CCCC[C@@H]4N)nc23)c(n1)C(F)F |r| |
|---|
| Structure | 
|
|---|
Search and Browse
